CHARLOTTESVILLE, Virginia, July 13, 2010 /PRNewswire/ — Biovista announced today the appointment of Mr. Clifford H. Farrah, President and Chairman of The Beacon Group, to its Advisory Board.
“We are very excited to have Cliff join our Advisory Board,” said Aris Persidis, President of Biovista. “Cliff brings a wealth of direct commercial development experience in the healthcare and biotech market that will be invaluable to us as we grow Biovista,” he added.
“Biovista is a new generation biotechnology company with unique technology and capabilities,” said Mr. Farrah. “It’s rare that you get the opportunity to help a company lead in the new order of drug discovery and development. Biovista is offering a disruptive, rigorous and efficient approach to a costly process, and I am excited to participate in its future.”
The Beacon Group is a strategy consulting firm providing guidance to organizations on their most critical business issues. With a clear focus on achieving top-line growth through both organic and inorganic means, Beacon’s output is designed to have a direct impact on client profitability. Healthcare practice base includes Fortune 100 biotech, pharmaceutical, medical device and diagnostics companies.
About Biovista (https://www.biovista.com):
Biovista is a privately held biotechnology company that finds novel uses for existing drugs, and profiles their side effects using their mechanism of action. Biovista is developing its own pipeline of drugs in multiple sclerosis, epilepsy, specific cancers and auto-immune diseases. Also, Biovista is collaborating with the FDA on prediction of adverse events, and with biopharmaceutical companies on indication expansion and de-risking of their portfolios.
For further information please contact:
Dr. Aris Persidis
Biovista, Inc.
arisp{at}biovista.com
+1-434-242-6514